

10/583334

(2)

6 AP3 Rec'd PCT/PTO 16 JUN 2005

CLAIMS

1. The use of cystine and/or cysteine to prepare oral medicinal products for the prevention and treatment of oxidative stress resulting from
5 haemodialysis treatment in patients suffering from chronic kidney failure or for the treatment and prevention of acute or chronic kidney diseases or of End-Stage Renal Disease.
2. The use according to claim 1, for the prevention and treatment of oxidative stress resulting from haemodialysis treatment in patients suffering
10 from chronic kidney failure.
3. Use as claimed in claim 1 or 2, wherein the cystine and/or cysteine is administered in unit doses ranging from 200 to 1000 mg.
4. Use as claimed in claim 1, 2 or 3, wherein the cystine and/or cysteine is administered before and/or after haemodialysis treatment.
- 15 5. Pharmaceutical compositions for oral administration for the prevention and treatment of oxidative stress resulting from haemodialysis treatment in patients suffering from chronic kidney failure or for the treatment and prevention of acute or chronic kidney diseases, containing cysteine or cystine as active constituent.
- 20 6. A method for the prevention and treatment of oxidative stress resulting from haemodialysis in patients suffering from chronic kidney failure comprising the administration to said patient from 200 to 1000 mg of cystine and/or cysteine orally before and/or after the haemodialysis treatment.
7. A method for the prevention and treatment of patients suffering from
25 acute or chronic kidney failure comprising the oral administration to said patient from 200 to 1000 mg of cystine and/or cysteine.
8. A method for the prevention and treatment of patients suffering from End-Stage Renal-Disease comprising the oral administration to said patient

BEST AVAILABLE COPY

- 7 -

from 200 to 1000 mg of cystine and/or cysteine.

BEST AVAILABLE COPY